Yet the celebration was always tempered by an uncomfortable arithmetic problem. KRAS G12C accounts for only a minority of KRAS-driven cancers. The most common oncogenic variants, including G12D, G12V, and Q61 mutations, dominate pancreatic and colorectal disease and lack the reactive cysteine that made the first-generation inhibitors possible. A comprehensive review published in Medical Oncology by Srijita Chatterjee, Swati Arya, and colleagues surveys this rapidly shifting landscape, arguing that the field is now moving decisively beyond allele-specific G12C inhibition toward a strategy that is mutation- and context-dependent. The review synthesizes patent filings, clinical trial data, and preclinical discoveries to map where KRAS drug development is heading next.

Among the most consequential new chemical entities are non-covalent inhibitors that do not depend on a cysteine residue. MRTX1133, developed through structure-based design, binds the inactive, GDP-bound state of KRAS G12D with nanomolar selectivity and demonstrated striking anti-tumor activity in preclinical pancreatic cancer models. Its clinical descendants are now in human trials, and the commercial stakes are enormous. In 2025, Bayer announced a global license agreement with Kumquat Biosciences for the KRAS G12D inhibitor KBQ548, a deal valued at up to 1.3 billion dollars, while Verastem Oncology exercised its option for rights outside China to the G12D inhibitor GFH375, also known as VS-7375. These transactions signal that major pharmaceutical companies view non-G12C KRAS inhibition as the next major oncology franchise.

Perhaps the most conceptually ambitious approach comes from a different mechanistic family altogether: the tri-complex, or molecular glue, inhibitors. Compounds such as RMC-6236, a pan-RAS(ON) antagonist, do not simply occupy a pocket on KRAS. Instead, they chaperone KRAS into a complex with cyclophilin A, remodeling the protein’s surface so that it can no longer engage its downstream effectors, regardless of which mutation drives the cancer. Because this mechanism is largely mutation-agnostic, a single drug could in principle treat the entire spectrum of RAS-driven tumors. The related molecule RMC-9805 applies the same logic selectively to KRAS G12D, and early clinical presentations have reported encouraging antitumor activity with favorable safety profiles. The review highlights how these agents, discussed intensively at recent ESMO congresses, have moved from academic curiosity to some of the most closely watched programs in clinical oncology.

A third frontier is protein degradation rather than inhibition. ASP3082, a KRAS-directed degrader, recruits the cell’s ubiquitin-proteasome machinery to eliminate mutant KRAS itself rather than merely silencing it. Early reports describe efficacy in KRAS G12D-mutant non-small-cell lung cancer with a manageable toxicity profile. Degradation offers theoretical advantages over occupancy-based inhibition: it removes all of the protein’s scaffolding and effector functions at once, and it may sidestep some resistance mechanisms that arise when residual inhibitor-bound protein retains partial activity. The patent landscape reflects this diversification. World Intellectual Property Organization filings now cover KRAS G12D inhibitors, deuterated KRAS G12D compounds, macrocyclic RAS inhibitors, pan-KRAS inhibitors spanning G12A, G12C, G12D, G12R, G12S, G12V, G13D, and Q61H variants, KRAS G12V-specific inhibitors, and even farnesyltransferase inhibitors repurposed for KRAS-dependent cancers.

No single agent, however, is likely to conquer KRAS-driven cancer alone, and the review devotes substantial attention to rational combination strategies. Upstream of KRAS, the guanine nucleotide exchange factors SOS1 and SHP2 regulate reactivation of the pathway, and blocking them can prevent the feedback activation of wild-type RAS that otherwise constrains G12C inhibitor efficacy. Downstream, MEK inhibitors such as VS-6766 have shown clinical activity in KRAS-mutant cancers, and SHP2 inhibition has been shown to prevent adaptive resistance to MEK blockade across multiple models. In colorectal cancer, where EGFR signaling provides a potent escape route, combining KRAS G12C inhibitors with anti-EGFR antibodies has produced some of the field’s most impressive results: sotorasib plus panitumumab, adagrasib with or without cetuximab, and the next-generation inhibitor divarasib plus cetuximab have all demonstrated substantially improved response rates in refractory disease. Other rational pairings include CDK4/6 inhibitors for KRAS-mutant pancreatic cancer and immune checkpoint inhibitors, exploiting the fact that some KRAS inhibitors appear to enhance anti-tumor immunity.

Resistance, predictably, has emerged as the central clinical challenge. Acquired resistance to sotorasib and adagrasib arises through secondary mutations in KRAS itself, bypass activation of downstream MAPK signaling, and histologic transformation. Co-mutation patterns matter enormously: tumors harboring concurrent STK11/LKB1 alterations show both reduced immunotherapy benefit and distinctive resistance to KRAS inhibition, partly through an adeno-to-squamous transition that reprograms tumor identity. Epithelial-to-mesenchymal transition, a developmental program hijacked by cancer cells, drives both intrinsic and acquired resistance, while non-genetic adaptive mechanisms, including cell-type-specific rewiring of signaling networks, allow tumors to tolerate drug pressure without any new mutation at all. Liquid biopsies that detect circulating tumor DNA are becoming essential tools for monitoring these resistance mechanisms in real time, offering a dynamic alternative to tissue re-biopsy and enabling earlier switches in therapy.

The synthetic lethality concept, first articulated in the 1990s as a framework for anticancer drug discovery, provides another lens for exploiting KRAS addiction. Because mutant KRAS forces cancer cells into a state of profound dependency on compensatory pathways, inhibiting a partner gene that the cancer cell cannot survive without, even when that gene is dispensable in healthy cells, offers a therapeutic window. Screening efforts continue to identify such vulnerabilities, and the review argues that pairing these genetic insights with the new inhibitor classes could produce combinations tailored to the specific constellation of mutations within each patient’s tumor, an approach squarely aligned with the goals of precision oncology.

The regulatory and commercial environment surrounding these advances is itself a story of global competition and opportunity. Patent filings from Mirati Therapeutics, Array Biopharma, and numerous other applicants reveal an intense race to claim chemical space around KRAS, including combination patents pairing G12D inhibitors with SOS1 inhibitors. Clinical trial registries list dozens of active studies, and press releases announcing billion-dollar licensing deals now arrive with regularity. For patients with pancreatic cancer, where KRAS mutation is essentially universal and five-year survival remains dismal, the acceleration cannot come soon enough. The review’s authors conclude that the field has entered a genuinely new era: the question is no longer whether KRAS can be drugged, but which drug, which combination, and which molecular context will deliver the greatest benefit. As allele-specific inhibitors give way to pan-KRAS antagonists, degraders, and intelligently designed combinations, KRAS-mutant cancers are being transformed from a monolithic, untreatable category into a set of molecularly defined diseases, each with its own map of vulnerabilities and its own path to clinical translation.

Subject of Research: Emerging therapeutic strategies and clinical progress in targeting KRAS-mutant cancers beyond KRAS G12C inhibition

Article Title: Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers

Article References: Beyond KRASG12C: emerging therapeutic strategies, patent landscape, and clinical progress in targeting KRAS-mutant cancers. (n.d.). https://doi.org/10.1007/s12032-026-03392-6

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03392-6

Keywords: KRAS, KRAS G12C, KRAS G12D inhibitors, pan-KRAS inhibitors, RMC-6236, sotorasib, adagrasib, protein degraders, SHP2 inhibition, drug resistance, pancreatic cancer, precision oncology

Traditional cancer therapies have struggled to tackle proteins such as MYC and KRAS, which are notorious for driving aggressive tumor growth and evading most small molecule drugs and antibody-based treatments. These proteins are termed “undruggable” due to their intrinsically disordered structures and lack of well-defined binding pockets, leaving conventional drug design at a disadvantage. The Northwestern team circumvented these hurdles by developing a novel class of heterobifunctional polymers dubbed HYDRACs (HYbrid DegRAding Copolymers), which function with remarkable precision to snare and shuttle these elusive proteins toward their degradation.

The essence of HYDRAC technology lies in its dual-binding architecture. Each polymer is designed with two functional domains: one arm incorporates multiple copies of peptides capable of selectively binding target proteins like MYC and KRAS, while the other arm carries molecular cues that recruit the cell’s protein decay machinery. This bifunctional design enables the polymers to physically juxtapose the target protein with the degradation systems naturally embedded within the cell, overcoming the need for a traditional druggable pocket.

Experimental work demonstrated the efficacy of these polymers in cellular models representing a spectrum of cancers. When introduced into cultured cancer cells, HYDRACs selectively engaged MYC and KRAS proteins, resulting in their prompt degradation. This degradation halted oncogenic signaling cascades driven by these proteins, leading to cell death. More impressively, in animal models harboring tumors driven by MYC, these polymers localized preferentially within tumors and curtailed tumor progression without significant toxicity or side effects, highlighting the potential for in vivo therapeutic application.

One of the most daunting challenges in contemporary oncology is managing the mutational plasticity of cancer cells, particularly with proteins like KRAS. Although recent small molecule inhibitors have been developed for specific KRAS mutations, resistance emerges quickly as tumors evolve alternative pathways or mutate their drug-binding sites. HYDRAC-based degradation effectively neutralizes this problem by targeting the entire protein for disposal rather than inhibiting a specific site. As detailed by Professor Nathan Gianneschi—the lead researcher and a renowned expert in polymer chemistry—this method effectively drags the protein “kicking and screaming” into the cell’s degradation pathway, indifferent to mutation status or protein conformational changes.

The methodology holds promise not only for oncology but could potentially revolutionize therapeutic strategies across multiple disease domains. Neurodegenerative disorders, inflammatory conditions, and metabolic diseases often involve aberrant or harmful proteins that are challenging to target with conventional drugs. The modular design of HYDRAC polymers allows for customization against a diverse array of protein targets, effectively opening doors to a broad spectrum of proteinopathies previously deemed intractable.

From a molecular engineering perspective, the one-step polymer synthesis employed by Gianneschi’s group is particularly noteworthy. It enables rapid, scalable production of these proteomimetic polymers with high specificity and multivalency, providing multiple binding sites on a single polymer chain to increase avidity and efficacy. This synthetic flexibility stands in contrast to small molecule strategies, which often require extensive medicinal chemistry optimization and face limitations imposed by the necessity of precise binding pockets.

Moreover, the theoretical underpinning of HYDRAC’s mechanism capitalizes on cellular quality control systems such as ubiquitin-proteasome pathways and autophagy. By co-opting these endogenous pathways, HYDRACs leverage the cell’s intrinsic mechanisms for protein homeostasis rather than relying on external enzymatic activity or immune-mediated clearance. This endogenous engagement minimizes off-target effects and enhances the likelihood of sustained therapeutic response.

The successful proof-of-concept studies published by the Northwestern team demonstrate the potential for translation from bench to bedside. Northwestern’s tech transfer and associated spinout company, Grove Biopharma, are actively developing the HYDRAC platform within the framework of “Bionic Biologics,” aiming to expedite clinical application. This translational push is supported by grants from various prestigious institutes, reinforcing the significance and potential impact of this research.

Importantly, the potential for multivalent polymer-based degraders extends beyond static protein targets. Given the dynamic and disordered nature of many pathological proteins, the ability of HYDRACs to adapt to variations and mutations makes it a versatile platform that could surmount longstanding obstacles in drug resistance and target selectivity. The polymers’ capability to bind disordered regions affords a new paradigm in drug design, shifting focus from rigid lock-and-key interactions toward adaptable, multivalent binding polymers.

While much remains to be explored, including long-term safety profiles, pharmacokinetics, and efficacy across diverse human tumors, the initial data provide compelling evidence that targeted protein degradation mediated by synthetic polymers represents a viable and transformative avenue in oncology and beyond. This research not only deepens our understanding of protein biology but also pioneers a new front in the war against cancer by transforming the cell’s disposal systems into strategic allies.

The study titled “Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS” propels the field forward, combining meticulous polymer chemistry with cellular biology to address formidable challenges posed by disordered cancer proteins. As targeted therapies evolve, this technology points toward a future where “undruggable” proteins can be effectively eliminated rather than inhibited, offering renewed hope for patients burdened by aggressive cancers and, potentially, other devastating diseases.

Subject of Research: Animals

Article Title: Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

News Publication Date: 24-Feb-2026

Web References: https://doi.org/10.1038/s41467-026-68913-3

Keywords: Cancer, Proteins, Cellular proteins, Cancer cells, Cancer treatments

Transcription factors are integral to the process of gene expression, acting as critical regulators that manage the on and off states of genes. Their role in cancer development is profound, as mutations and overexpression can lead to unchecked cell growth, a hallmark of malignant transformation. Until recently, attempts to create small molecule drugs that effectively inhibit these proteins have met with limited success. Peptide-based therapies have emerged as an alternative strategy, leveraging small protein fragments to bind and block the activity of these challenging targets.

Researchers at the University of Bath have unveiled a technique employing a novel drug discovery platform known as the Transcription Block Survival (TBS) assay. This assay allows scientists to test a vast library of peptide fragments, seeking those that can effectively “switch off” transcription factors driving cancer progression. By screening a myriad of peptides, the researchers were able to identify compounds designed to interact specifically and irreversibly with the transcription factor cJun, which has been linked to aggressive cancer phenotypes.

The innovative approach not only focuses on identifying reversible inhibitors but pushes the boundaries by successfully engineering peptides that can bind irreversibly to cJun. The technical design of these peptides allows them to latch onto one of the two identical halves of cJun, effectively preventing these halves from pairing and subsequently attaching to DNA. This dual-lock mechanism not only diminishes cJun’s ability to transactivate its target genes but also solidifies the peptide’s grip on the transcription factor, creating a robust and lasting blockade.

Dr. Andy Brennan, a key figure in this study and Research Fellow in the Department of Life Sciences at the University of Bath, likens the mechanism of the peptide to a harpoon that is launched toward its target with the intent to remain attached. This high-affinity binding strategy is critical in ensuring that cJun cannot resume its active role in the cell, which is crucial for furthering cancer cell proliferation. This represents not just a theoretical advancement but a practical methodology that has been tested successfully within a cellular context.

The TBS assay works by introducing binding sites for cJun within essential genes in cultured cells. When cJun binds, it effectively silences these genes, leading to cellular demise. Conversely, the application of the newly developed peptide inhibitor allows the gene activity to be reinstated, resulting in the survival of the cells. This direct measurement in a relevant biological environment marks a significant improvement over traditional drug screening methodologies that often fail to account for complex intracellular interactions.

The implications of this research extend far beyond cJun and underscore the potential for this peptide-based approach to be applied to other previously deemed "undruggable" targets. Many conventional pharmaceuticals have struggled with issues of cell permeability and toxicity; however, this direct cellular approach mitigates some of these obstacles, opening avenues for the discovery of new drug candidates. Jody Mason, Chief Scientific Officer at Revolver Therapeutics, emphasizes that testing in vivo responses to peptides could spur the identification of additional promising therapeutics that address a broader spectrum of oncogenic drivers.

This study lays the groundwork not only for potential treatment avenues for cancers driven by cJun but also signals a paradigm shift in drug discovery for difficult protein targets. With the rigorous validation of the peptides’ activity in cancer cells, researchers are now poised to advance to preclinical cancer models, where they will test the efficacy and safety of these innovative inhibitors in live biological systems. This next step is crucial for understanding how these peptides behave in more complex living organisms.

Funding for this impactful research was provided by esteemed agencies including the Medical Research Council and the Biotechnology and Biological Sciences Research Council, amplifying the outreach and resources necessary for pioneering scientific inquiry. By overcoming significant barriers in rational drug design and creating a viable platform for the development of peptides, this project could herald a new age in targeted cancer therapies, equipped to tackle the intricacies of oncogenic proteins that have so far resisted conventional therapeutic interventions.

As the field of cancer research continues to evolve, this work represents a crystallization of innovative thinking and collaborative effort that could yield significant benefits for clinical oncology. The scientists at the University of Bath are not just addressing existing challenges; they are pioneering new frameworks for future drug discovery that could have sweeping implications across various fields of medicine, particularly in the fight against cancer. The promise of irreversible transcription factor inhibitors transcends the experimental realm, anticipating translations to tangible treatments that could alter the prognosis of patients battling various forms of cancer.

This momentous achievement not only highlights the capabilities of peptide engineering but is also a testament to the relentless human pursuit of knowledge in the face of daunting biological complexities. The identification of these irreversible covalent transcription factor inhibitors serves as both a beacon of hope for patients and a clear signal to the scientific community of the potential that lies within reimagining drug development strategies. With further exploration and validation, these findings could very well inspire a new generation of therapeutics capable of tackling the formidable challenges posed by cancer.

Subject of Research: Cells
Article Title: An Intracellular Peptide Library Screening Platform Identifies Irreversible Covalent Transcription Factor Inhibitors
News Publication Date: 17-Mar-2025
Web References: Advanced Science
References: 10.1002/advs.202416963
Image Credits: (Not provided)

Keywords: Cancer research, Drug research, Discovery research, Peptides, Transcription factors, Molecular targets, Drug candidates, DNA binding proteins.